17-Apr-2026
Smith+Nephew signs distribution agreement with SI-BONE
Globe Newswire (Mon, 23-Feb 4:30 PM ET)
SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2025 and Issues 2026 Guidance
Globe Newswire (Mon, 23-Feb 4:09 PM ET)
SI-BONE To Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
Globe Newswire (Tue, 17-Feb 4:30 PM ET)
SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026
Globe Newswire (Mon, 2-Feb 4:30 PM ET)
SI-BONE Projects 20% Revenue Growth in 2025—Physician Base and Cash Reserves Also Expand
Market Chameleon (Mon, 12-Jan 4:39 AM ET)
SIBN Lifts 2025 Outlook After Delivering 21% Revenue Growth and Positive Cash Flow
Market Chameleon (Tue, 11-Nov 6:15 AM ET)
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Si-Bone trades on the NASDAQ stock market under the symbol SIBN.
As of April 17, 2026, SIBN stock price climbed to $14.09 with 361,391 million shares trading.
SIBN has a beta of 0.86, meaning it tends to be less sensitive to market movements. SIBN has a correlation of 0.06 to the broad based SPY ETF.
SIBN has a market cap of $622.29 million. This is considered a Small Cap stock.
Last quarter Si-Bone reported $56 million in Revenue and -$.04 earnings per share. This beat revenue expectation by $73,400 and exceeded earnings estimates by $.09.
In the last 3 years, SIBN traded as high as $29.51 and as low as $11.70.
The top ETF exchange traded funds that SIBN belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
SIBN has underperformed the market in the last year with a price return of +1.7% while the SPY ETF gained +36.3%. SIBN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.1% and +7.4%, respectively, while the SPY returned +2.9% and +8.3%, respectively.
SIBN support price is $13.17 and resistance is $14.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SIBN shares will trade within this expected range on the day.